HER2 Is Not a Predictive Biomarker of Benefit From Up-front Chemotherapy Plus Bevacizumab or Anti-EGFR, but Negative Prognostic Factor in pMMR/MSS RAS/BRAF Wild-Type mCRC By Ogkologos - September 29, 2025 271 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a large analysis of HER2 status in patients enrolled in 8 randomised clinical trials Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR 177Lu-DOTATATE Shows Promising Efficacy in the Treatment of Patients with Progressive... September 2, 2025 Safety and Preliminary Signs of Activity of OMO-103, a MYC Inhibitor,... February 9, 2024 Efficacy Outcomes of Repotrectinib in Patients with NTRK-positive Solid Tumours February 10, 2026 Delivering the future of paediatric brain tumour therapy October 7, 2021 Load more HOT NEWS Woman, 88, Had Been Waving from Her Window for Over a... FDA Approves Ensartinib for ALK-positive Locally Advanced or Metastatic Non-Small Cell... Breast Cancer Centers Rarely Follow National Screening Recommendations, Study Says Woman With Double Mastectomy Invents Breastfeeding Simulator For Breast Cancer Survivors
